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Abstract
Background This article aims to comprehensively describe
indications, contraindications, technical aspects, diagnostic
accuracy and complications of percutaneous lung biopsy.
Methods Imaging-guided biopsy currently represents one of
the predominant methods for obtaining tissue specimens in
patients with lung nodules; in many cases treatment protocols
are based on histological information; thus, biopsy is frequent-
ly performed, when technically feasible, or in case other tech-
niques (such as bronchoscopy with lavage) are inconclusive.
Results Although a coaxial system is suitable in any case, two
categories of needles can be used: fine-needle aspiration biop-
sy (FNAB) and core-needle biopsy (CNB), with the latter
demonstrated to have a slightly higher overall sensitivity,
specificity and accuracy.
Conclusion Percutaneous lung biopsy is a safe procedure
even though a few complications are possible: pneumothorax,
pulmonary haemorrhage and haemoptysis are common com-
plications, while air embolism and seeding are rare, but poten-
tially fatal complications.
Teaching points
• Imaging-guided biopsy is one of the main methods to obtain
lung nodule specimens.
• CT has the highest accuracy for diagnosis as an imaging
guide.
• Compared to FNAB, CNB has a higher accuracy for
diagnosis.
• Pneumothorax and parenchymal pulmonary haemorrhage
care the most frequent complications.
• Several clinical and technical variables can affect diagnos-
tic accuracy and patient safety.
Keywords Lung lesion . Percutaneous biopsy .
Complication . Diagnostic accuracy . Fine-needle aspiration
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Introduction
Chest tumours, in particular lung cancer, remain one of the
most common causes of cancer-related death worldwide.With
the diffusion of spiral CT, an increasing number of lung and
mediastinal lesions is detected and histological diagnosis is
often necessary to determine the most appropriate manage-
ment of these lesions [1]. In this clinical scenario, imaging-
guided biopsy is one of the main methods to obtain tissue
specimens. Various imaging techniques including computed
tomography (CT) fluoroscopy and ultrasound (US) can be
used to guide chest biopsies, but CT is most frequently
employed because of its high spatial and contrast resolution
as well as its 3D imaging ability; in many cases CT is
preferred based on the localisation of the nodule or
other patient-related factors.
Clinical indication
Clinical indications of imaging-guided chest biopsy have sig-
nificantly changed from the introduction of the technique as a
result of technical advances in needle technology, imaging
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modalities, pathological analysis and immunohistochemistry
techniques. The introduction of PET-CT further modified
these indications, reducing the percentage of unnecessary bi-
opsies [2]. At present, the growing list of indications (Table 1)
includes histological diagnosis of undetermined and otherwise
not characterisable pulmonary, mediastinal and chest wall le-
sions as well as biopsy or re-biopsy of known malignant le-
sions to obtain histological material for targeted therapy.
(Fig. 1).
A new or enlarging solitary nodule or mass
The increasing clinical use of chest CT has resulted in an
increasing incidental detection of small pulmonary nodules.
In particular, pulmonary nodules are incidentally detected in
around 8.5% of the general population [3] and in up to 51% of
subjects with risk factors [4]. Therefore, a new or enlarging
solitary nodule is the most common indication for imaging-
guided chest biopsy. If a nodule is initially identified at con-
ventional chest radiography, CT investigation is necessary to
characterise the lesion, estimate the likelihood of malignancy
[5] and identify lymphadenopathies or other accessible sites
for biopsy (such as extra-thoracic metastases) [6, 7]. PET-CT
examination may also be helpful in the management of pul-
monary nodules larger than 1 cm, reducing the need of punc-
ture of non-enhancing solid nodules [4–8] and with a sensi-
tivity of 94% and a specificity of 83% for solid pulmonary
nodules between 1 and 3 cm in diameter [9]. It must be
taken in consideration that active inflammation (i.e. ac-
tive tuberculosis, histoplasmosis, rheumatoid nodules)
may cause false positives on PET-CT scans because of
their high glucose metabolism [10]. On the other hand,
low-grade malignant tumours, such as carcinoid [11] or
low-grade adenocarcinoma [12], may produce false-
negative results because of their low glucose metabo-
lism. In these cases, careful follow-up with CT must
be performed according to well-established guidelines
to demonstrate regression/disappearance of the nodule
after therapy or to address patients to biopsy if persis-
tence or increase in size are evident [13].
Multiple nodules in a patient without known neoplastic
disease or in prolonged remission
Several benign conditions can appear with slowly enlarging or
multiple new pulmonary nodules, such as rheumatoid arthritis,
sarcoidosis or infectious diseases, including tuberculosis and
fungal infections, particularly in immunosuppressed patients
[14–16]. In these cases appropriate clinical work-up and CT
follow-up are sufficient to exclude malignancy. Nevertheless
multiple nodular lesions may be the initial metastatic presen-
tation in a patient with an unknown primary tumour or the sign
of disease progression in a patient with known primary
tumour in prolonged remission. In these cases imaging-
guided biopsy may be necessary to confirm or exclude
malignancy.
Focal parenchymal infiltrates in which an infectious
organism cannot be isolated
When infectious organisms cannot be isolated from the
culture of sputum, blood or lung lavage, lung biopsy
can be necessary to obtain tissue samples for patholog-
ical examination. The biopsy sample can be cultured for
diagnostic purposes to establish the most appropriate
pharmacological treatment. Imaging-guided biopsy was
demonstrated to have a sensitivity of 80% and a posi-
tive predictive value of 100% [17, 18].
Diagnosis of hilarmasses following negative bronchoscopy
Transbronchial needle aspiration during bronchoscopy or un-
der ultrasound guidance is still considered the reference tech-
nique for the diagnosis of hilar masses [19, 20]. However,
when bronchoscopy cannot be performed or is inconclusive,
hilar masses can be accurately diagnosed by imaging-guided
biopsy.
Undiagnosed mediastinal mass
Mediastinal masses are most frequently located in the anterior
mediastinum and include a variety of different entities, such as
thymic malignancy, lymphomas, endocrine tumours and ma-
lignant germ cell tumours [21]. In the absence of typical clin-
ical and imaging features, histological diagnosis is necessary
[22]; imaging-guided biopsy should be always attempted
in accessible lesions before diagnostic mediastinoscopy
or in case of inconclusive results of mediastinoscopy.
Biopsy or re-biopsy of malignancy for targeted therapy
Advanced non-small-cell lung cancer in progression after
first-line therapymay need imaging-guided re-biopsy to detect
Table 1 Indications for imaging-guided chest biopsy
Indications for imaging-guided chest biopsy
1. A new or enlarging solitary nodule or mass
2. Multiple nodules in a patient without known neoplastic disease or in
prolonged remission
3. Focal parechymal infiltrates in which an infectious organism cannot be
isolated
4. Diagnosis of hilar masses following negative broncoscopy
5. Undiagnosed mediastinal mass.
6. Bipopsy or re-biopsy of malignancy for targeted therapy.
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a possible new biological profile and to guide therapeutic
decision-making in more than one-third of cases. [23].
Contraindications
Because of moderate risk of bleeding, abnormal clotting func-
tion or thrombocytopenia should be recognised and corrected
before the procedure. Thus, oral anticoagulants and
antiaggregant drugs should be reduced or stopped to reach
an international normalised ratio (INR) of less than 1.5 and
an activated partial thromboplastin time (aPTT) not more than
1.5 times the control value; platelet transfusion is recommend-
ed for counts <50,000/μl (Table 2) [24]. Suspected hydatid
cyst or arterio-venous malformation should not be biopsied
but can be identified on CT. Mechanical ventilation, which
may lead to pneumothorax and favours air embolism, inability
of a patient to co-operate during the procedure or to suspend
respiration on request or control cough are the major contra-
indications. A unique functional lung is often considered an-
other contraindication, while severe chronic obstructive pul-
monary disease, pulmonary hypertension or cardiac insuffi-
ciency do not constitute absolute contraindications but in-
crease the complication rate. [25].
Imaging guidance techniques
CT, fluoroscopy and US may all be used to guide chest biop-
sies and operators should be familiar with the advantage and
limitations of each one [26]. Parameters affecting the selection
of the most appropriate imaging technique are lesions site, size
and visibility as well as its relationship with critical anatomical
structures to be avoided [5]. Whenever possible, chest biop-
sies should be performed under US guidance (Fig. 2) to ex-
ploit the advantages of real-time monitoring without radiation
exposure to patients and operators [27]; however, US guid-
ance is limited to superficial lesions adjacent to the chest wall
and/or to lesions delineated by pleural effusion sufficient to
Table 2 Abnormal values that should be corrected before the procedure
Patient management before procedures with moderate risk of bleeding
INR Correct to <1.5
aPTT Should be corrected for values >1.5 × control
Plateles Transfusion recommended for count <50.000/μl
Fig. 1 Indications for CT-guided
chest biopsy. (a) Solitary
pulmonary nodule. (b)
Parenchymal infiltrates in which
an infectious organism cannot be
isolated. (c) Hilar mass following
negative bronchoscopy. (d)
Undiagnosed mediastinal mass
Fig. 2 Ultrasound-guided chest biopsy of a pulmonary nodule in the
right lower lobe
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create a suitable interface for ultrasound penetration. In the
vast majority of cases, CT (or cone-beam CT) (Figs. 3 and
4) is the preferred guidance method for chest biopsies due to
its optimal spatial and contrast resolution as well as its 3D
imaging ability. Furthermore an intravenous contrast agent
can be used to differentiate target lesions from atelectasis,
necrosis and vascular structures. CT-guided chest biopsies
can be performed either with the step-and-shoot approach or
with CT-fluoroscopy (Fig. 5): while the step-and-shoot ap-
proach allows 3Dmultiplanar reconstruction and significantly
reduces the radiation dose to the patient and operators, it does
not allow real-time monitoring of lesion movement during
respiration and is strongly influenced by the patient compli-
ance. On the other hand, real-time monitoring of lesions
movement with CT-fluoroscopy guidance allows reducing
needle passes and procedure time; however, the radiation dose
(to both the patients and operator) is significant [28]. To sim-
plify the approach and to increase the speed and reliability of
step-and-shoot CT-guided chest biopsies, several technical ad-
vances have been proposed, including augmented reality and
use of robotic platforms [29].
Furthermore, if a PET/CT is available, the needle should be
led to the most enhancing area of the lesion to increase diag-
nostic accuracy.
Biopsy procedure
Patient positioning and instruction
The patient should be positioned prone, supine or lying on the
side, based on the previously planned access site and needle
trajectory. When needed, arms can be raised above the head to
widen the intercostal spaces and obtain easier access. The
procedure should be adequately explained to the patients with
emphasis on the potential stinging sensation during the pleural
puncture and breath-hold phases.
Access site
Whenever possible, the needle access site should be cephalic
to the ribs to avoid intercostal vessel and nerves puncture
(Fig. 6) [30]. In case of anterior parasternal access, inter-
nal mammary vessels should be carefully avoided [31].
Costal cartilage may traversed if needed but this may
result in reduced needle mobility. The skin in the access
site should be sterilised with standardised antiseptic so-
lution and cutaneous and subcutaneous tissues should be
infiltrated with lidocaine (lignocaine) up to a maximum
dose of 20 ml of a 2% solution.
Fig. 3 CT-guided chest biopsy of
a pulmonary nodule in the left
lower lobe. (a) Axial, (b) coronal
and (c) sagittal intraprocedural
CT scans showing the needle tip
in the lesion (arrow)
Fig. 4 Axial images during fluoroscopy-guided chest biopsy of a solitary subpleural nodule
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Breath-hold techniques and needle manipulation
The breath-hold technique stabilises the positions of the dia-
phragm, pleural planes, lung, fissures and, ultimately, target
lesions; however, breath-hold capabilities can be extremely
different from patient to patient, and even the same subject
may not be able to reproduce breath-hold during the procedure
because of stress or fatigue. Therefore, it can be easier to target
larger tumours (>2/3 cm) instructing the patient to breath free-
ly with shallow respiration; even though the target lesions
moves slightly, its large size may be sufficient to require few
adjustments. In the remaining cases, the patient can be
instructed to maintain an inspiratory or expiratory apnoea to
allow easier access to target lesions.
Needle types
Needle choice is based on the size and location of the lesion,
intended needle trajectory, information expected from the
pathologic sample, status of the lung parenchyma and operator
preference. Some of the more commonly used fine-needle
aspiration (FNA) devices include Chiba, Franseen, Westcott,
MaxiCELL, Greene (Cook) and Turner (Cook) needles,
which have circumferentially sharpened tips allowing for sam-
pling. Core biopsy needles are designed to collect a small
piece of tissue intended for surgical pathology analysis and
can be designed as end-cutting or side-cutting devices. The
most commonly used core biopsy needle is the Tru-Cut, which
consists of an outer cutting cannula and an inner slotted stylet.
The Temno core biopsy device is another similar commonly
used automatic core biopsy needle. The Biopince full core is
an automated end-cutting needle that produces a full cylindri-
cal core specimen. The decision to perform core biopsy or
both core biopsy and FNA is multifactorial and highly insti-
tution-/operator-dependent [28]. The number of passes needed
per procedure has not been defined, but the decision to per-
form more than one puncture depends on procedure difficulty,
risk of complications, quality of the first specimen obtained
and the pathologist’s requests. The presence of an on-site pa-
thologist may reduce the number of biopsies needed [5]. Also
Fig. 5 Progressive images of Cone-beam-guided chest biopsy of a pulmonary nodule in the left upper lobe
Fig. 6 (a) Axial CT image and
(b) 3D reconstruction showing
internal mammary arteries
(arrows), which must be avoided
during the procedure
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the use of a coaxial, a larger-bore needle that is kept in place to
maintain access to the target lesion, may allow multiple tissue
sampling, reducing repeated pleural or soft tissue punctures
[32]. Several techniques have been proposed to seal the path
of the needle after its removal to reduce the risk of pneumo-
thorax and haemorrhage; the most successful option is to cre-
ate a blood patch with autologous venous blood [33, 34].
Diagnostic accuracy
Ultrasound versus CT
In a recent meta-analysis, Di Bardino et al. compared the diag-
nostic accuracy of ultrasound and CT-guided thoracic biopsy.
The overall pooled diagnostic accuracy of ultrasound-guided
biopsy was 88.7% (446/503), with a sensitivity of 91.5% (366/
400) and a specificity of around 100% for the diagnosis of
malignancy. The overall pooled diagnostic accuracy of CT-
guided biopsy was 92.1% (9567/10,383), with a sensitivity of
92.1% (7343/7975) and a specificity of around 100% for the
diagnosis of malignancy (Tables 3 and 4) [35]. These data show
a relative superiority of CT as guidance method, but data on
CT-guided biopsies weremore significant because of the higher
number of cases in comparison with US-guided biopsies.
FNAB versus core biopsy
There is a wide variation in reporting diagnostic accuracies of
fine-needle aspiration biopsy (FNAB) between different insti-
tutions, ranging from 64% to 97%. The false-negative rate of
FNAB varies, occurring in 6 to 54% of biopsies. The sensi-
tivity, specificity and accuracy of FNAB for pulmonary le-
sions are 82 to 99%, 86 to 100% and 64 to 97%, respectively
[28]. Core biopsy has been shown to have slightly higher
overall sensitivity, specificity and accuracy, with respective
values of 89%, 97% and 93% (Table 3). Several recent papers
advocate the use of 18- and 20-gauge cutting needles as well
as coaxial techniques to improve the diagnostic yield,
reporting diagnostic accuracies of 74–95% for the diagnosis
of malignancy. Charig and Phillips reported similar accuracy
of FNAB and core biopsy when an on-site pathologist was
available; in a similar setting Capalbo et al. observed a greater
diagnostic accuracy of FNAB compared to core needle biopsy
(94.83% vs. 81.82. %) [36]. Nowadays, the test of genetic
mutations is important to plan targeted therapies in patient
with lung cancers. With regard to this point, Schneider et al.
observed a statistically significantly higher number of samples
sufficient for molecular testing in core biopsy than FNAB
(67% vs. 46%; P = 0.007) [37].
Central versus peripheral lesions
Various studies evaluated the effects of lesion location on the
diagnostic accuracy of imaging-guided biopsy in chest tu-
mours. In a paper from Layfield et al. [38], the sensitivity in
diagnosing lung tumours decreased from 100% in peripheral
lesions to 82% in central lesions; however, this study was
conducted in 1996 with basic CT equipment, as demonstrated
by the striking differences in sensitivity between fluoroscopy
guidance (97%) and CT guidance (80%). Yamagamy et al.
[39] demonstrated that some peripherally located lesions are
not accessible at all with conventional CT guidance because of
their relationship with rib arcs, thus requiring needle position-
ing under CT-fluoroscopy guidance. Finally, Wang et al. [40]
recently compared the rates of complications and diagnostic
accuracy of CT-guided biopsy in peripheral versus
paramediastinal lesions, demonstrating how this technique
may be safe and reliable even for deeply located tumours; in
particular, their paper reports diagnostic accuracy of 95.4% in
paramediastinal lesions and 94.7% in peripheral lesions, with
a sensitivity of 95.6% and 94.2% respectively (Table 3).
Post-procedural care and complications
Once the biopsy has been performed, a CT scan of the chest is
obtained to identify any immediate post-procedural
Table 3 Test characteristics for
different imaging guidance
techniques (ultrasound vs. CT),
biopsy techniques (FNAB vs.
core biopsy) and lesion location
(pamediastinal vs. peripheral)
Accuracy Sensitivity Specificity
Imaging guidance techniqueE Ultrasound-guide biopsy 88.7% 91.5% 100%
CT-guide biopsy 92.1% 92.1% 100%
Biopsy technique FNAB 64–97% 82–99% 86–100%
Core biopsy 93% 89% 97%
Lesion location Paramediastinal 95.4% 95.6% 100%
Peripheral 94.7% 94.2% 100%
Table 4 Safety profile of imaging-guided biopsy
PTX Haemorrhage
CT-guided biopsy 20.5% 2.8%
Ultrasound-guided biopsy 4.4% –
Fluoroscopy-guided biopsy 11.1% –
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complications. According to some authors, the patients should
be rolled over onto the punctured side to reduce the risk of
delayed PNX; anyway, this is a controversial opinion, since
other authors have reported no benefits of putting patients in
the Bbiopsy down position^ [41]. Following measures include
observation andmonitoring of vital signs for at least 4 h. Chest
films are usually acquired after 4 h to detect possible asymp-
tomatic PNX. If the clinical suspicion of a PNX arises, chest
radiography must be obtained immediately. In low-risk pa-
tients, many interventional radiology services reasonably per-
form lung biopsies on an outpatient basis, with discharge at
4 h and readmission only if symptoms develop [42].
Pneumothorax
PNX is the most common complication after imaging-guided
chest biopsy; it is most frequently detected after lung biopsy
but can also occur even after biopsies of mediastinal, pleural
and chest wall lesions. Usually PNX occurs during or imme-
diately after the procedure and it is detected on post-
procedural control scans. The incidence of PNX has been
reported to be up to 61% with an average risk of 20%
[43–46]. Risk factors for PNX can be related to patient or
lesions features, but also to the biopsy technique. In particular,
the rate of PNX increases with the patient age and severity of
underlying lung disease (e.g. emphysema or chronic obstruc-
tive disease) [47, 48] as well as in smaller and deeper lesions
[49, 50]. Technical risk factors include the type and size of
biopsy needle, longer procedure duration, biopsies in the mid-
dle or lower lobe, transgression of a fissure and multiple nee-
dle repositioning or pleural passes [51]. A PNX developed
during the procedure can be immediately aspirated through
the introducer needle or a separate needle inserted into the
pleural space, preventing further enlargement; however some
authors suggest placing a chest tube if aspirated air is greater
than 670 ml [40]. PNXs developed after the procedure (Fig. 7)
are often small and asymptomatic and can be managed con-
servatively by monitoring vital signs and performing serial
chest films (at 1 and 4 h) [45, 52]. Nevertheless, in a minority
of cases (1–14%), PNX can be significant (>30% of lung
volume), increase over time or become symptomatic. In these
cases small-calibre, 6- to 9-French catheters can be safely and
easily placed under CT guidance [41, 53, 54].
Pulmonary haemorrhage and haemoptysis
Pulmonary haemorrhage represents the second most common
complication after imaging-guided biopsy. PHmay occur with
or without haemoptysis and can be easily detected on screen-
ing post-biopsy CT scan as a perilesional or needle tract
ground-glass opacity (Fig. 8). The occurrence rates of PH
are estimated to be from 4 to 27% (with an average incidence
of 11%), while haemoptysis risk is up to 5% [55, 56]. Usually
this complication does not need any treatment and the only
recommendations is to place the patient in a lateral position,
with the biopsy side down, to avoid aspiration of blood into
the unaffected lung [44]. Occasionally a larger, higher-grade
PH occurs and oxygen as well as pro-coagulative therapy may
be needed. Risk factors for higher-grade PH include older age,
female sex, emphysema, pulmonary hypertension, coaxial
technique, subsolid lesions, nonsubpleural location and lesion
size smaller than 3 cm [57, 58]. Avoiding PH is important to
manage patients with abnormal coagulation profiles and to
correct the diathesis before the procedure. In such pa-
tients, more invasive biopsy techniques that imply the
use of the core needle and coaxial technique should be
avoided as should prolonged procedures with extended
needle paths [45, 59]. Finally, haemothorax is an ex-
tremely rare and more severe complication, usually due
to puncture of an intercostal or less commonly a large
thoracic vessel, or mammary vessels in the case of an
anterior parasternal biopsy.
Air embolism
The occurrence of systemic air embolism (SAE) in the left
atrium, left ventricle or systemic circulation is a rare (inci-
dences between 0.01% and 0.21%), but potentially fatal (by
Fig. 7 CT-guided chest biopsy of
solitary pulmonary nodule in the
left lower lobe. (a) Axial CT
image before the procedure
showing the subpleural nodule.
(b) Post-procedural axial CT
image showing small PNX
(arrows) as a complication of
transthoracic biopsy
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brain or cardiac infarct) event [59] (Fig. 9). There are three
mechanisms in particular responsible for SAE during biopsy:
placement of the needle tip in a pulmonary vein, formation of
a bronchial-venous or alveolar-venous fistula and opening the
outer cannula of a coaxial biopsy needle to the atmosphere.
Risk factors can be biopsy of cystic or cavitary lesions (i.e.
vasculitic granulomas), coughing during the biopsy and pos-
itive pressure ventilation [60]. In a study from Freund et al.,
asymptomatic SAE detectable at CT after lung biopsy was
reported to be as high as 3.8% (23/610 patients), whereas
the symptomatic cases were 0.49%. In the meta-analysis from
Tomiyama et al. [61, 62], the incidence of SAE ranges from
0.001% to 0.003%, being influenced by the depth of needle
penetration into the lesion, endotracheal anaesthesia, location
of the lesion above the level of the left atrium and prone
position of the patients [61].
Tumour seeding
Tumour seeding through the needle tract represents a very rare
complication with a prevalence reported in the literature be-
tween 0.012 and 0.061% [45]. The real clinical relevance is
still discussed, but it is obvious that tumour seeding
along the needle tract can significantly change patient
management and life expectancy and should be strictly
avoided [63]. Tumour seeding is reported to be more
frequently observed after imaging-guided core needle
biopsy of pleural mesothelioma [64].
Complications by imaging guidance technique
In the meta-analysis from Di Bardino et al. US-guided
biopsy was generally very well tolerated and safe, with
a pooled incidence of PNX of 4.4% (22/503) in the
reported papers. This looks favourable compared to
CT-guided biopsy, but is also obviously correlated to a
statistical bias in lesion position since the targets of US-
guided biopsies are usually adjacent to or infiltrating the
pleural surface, with a very low risk of PNX.
Compared with the conventional step-and-shoot approach
for CT-guided biopsy, CT fluoroscopy is faster and requires
fewer needle passes, resulting in a decrease of procedure du-
ration and fewer complications. In particular Heck et al. [48]
showed a trend toward a lower PNX rate when using
CT fluoroscopy as guidance method. Similar results
have been obtained by Kim et al. [65], with a decrease
from 27.1% to 11.1% in PNX rates when using CT
fluoroscopy.
Fig. 9 Post-procedural CT scan
after chest biopsy showing two
different patients with air
embolism in cerebral vessels
(arrows)
Fig. 8 CT-guided chest biopsy of
a pulmonary nodule. (a) Axial CT
image before the procedure
showing a pulmonary nodule in
the right lower lobe. (b) Post-
procedural axial CT image
demonstrates perilesional
haemorrhage as ground-glass
opacity around the nodule
(arrows)
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Conclusions
In conclusion, imaging-guided chest biopsy is an intervention-
al procedure of pivotal importance for several clinical condi-
tions of pneumological, oncological and surgical interest. This
procedure may appear very simple and linear, but radiologists
approaching it for the first time must consider several clinical
and technical variables significantly affecting the final results,
in terms of both diagnostic accuracy and patients’ safety.
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